Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company''s lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer''s disease (AD) and Parkinson''s disease, as well as is in clinical trials for Alzheimer''s disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Latest shares articles
What currencies are pegged to USD?
Learn all about the US dollar’s pegs, including why countries peg their currencies to USD, and how it can affect forex trading.
4 hours ago
Is the US bond market on the brink of a dangerous debt death spiral?
Ray Dalio, the billionaire hedge fund manager who predicted the 2008 market crash, is once again raising the alarm about an economic breakdown worse than a recession.
22 hours ago
Why platinum just broke a decade long resistance
A line can be drawn on platinum's price chart starting in 2008, capturing one, two, three, four reactions over 17 consecutive years.
22 hours ago
Trading the Dow: Earnings steal the show
The value of the key US equity index lagged last week against those with heavier tech weightings, but its technical overview remains bullish and still a story of net long bias for CoT speculators.
09:00, 21 July 2025
Ratings and Reviews
Ratings and Reviews
